Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Cited by (363)

Items 201–300 of 363

1. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress
   Luna-Marco, Clara, Iannantuoni, Francesca, Hermo-Argibay, Alberto, Devos, Deédeni, Salazar, Juan D., Víctor, Víctor M., Rovira-Llopis, Susana · 2024 · Free Radical Biology and Medicine
2. Effects of SGLT2 inhibitors on stroke and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis.
   Tsai, Wen-Hsuan, Chuang, Shih-Ming, Liu, Sung-Chen, Lee, Chun-Chuan, Chien, Ming-Nan, Leung, Ching-Hsiang, Liu, Shu-Jung, Shih, Hong-Mou · 2021 · Scientific Reports
3. Canagliflozin ameliorates renal oxidative stress and inflammation by stimulating AMPK-Akt-eNOS pathway in the isoprenaline-induced oxidative stress model
   Hasan, Raquibul, Lasker, Shoumen, Hasan, Ahasanul, Zerin, Farzana, Zamila, Mushfera, Parvez, Faisal, Rahman, Md. Mizanur, Khan, Ferdous, Subhan, Nusrat, Alam, Md. Ashraful · 2020 · Scientific Reports
4. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
   The EMPA-KIDNEY Collaborative Group, Herrington, William G, Wanner, Christoph, Green, Jennifer B, Hauske, Sibylle J, Judge, Parminder, Mayne, Kaitlin J, Ng, Sarah Y A, Sammons, Emily, Zhu, Doreen et al. · 2022 · Nephrology Dialysis Transplantation
5. Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline
   Doyle-Delgado, Kacie, Chamberlain, James J., Shubrook, Jay H., Skolnik, Neil, Trujillo, Jennifer · 2020 · Annals of Internal Medicine
6. Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
   Dekkers, Claire C. J., Sjöström, C. David, Greasley, Peter J., Cain, Valerie, Boulton, David W., Heerspink, Hiddo J. L. · 2019 · Diabetes, Obesity and Metabolism
7. The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials
   Lin, Donna Shu-Han, Lee, Jen-Kuang, Hung, Chi-Sheng, Chen, Wen-Jone · 2021 · Diabetologia
8. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
   American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, Mandeep, McCoy, Rozalina G., Balapattabi, Kirthikaa, Bannuru, Raveendhara R., Bellini, Natalie J., Bennett, Allison K., Beverly, Elizabeth A., Briggs Early, Kathaleen, ChallaSivaKanaka, Sathyavathi et al. · 2026 · Diabetes Care
9. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
   American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, Mandeep, McCoy, Rozalina G., Balapattabi, Kirthikaa, Bannuru, Raveendhara R., Bellini, Natalie J., Bennett, Allison K., Beverly, Elizabeth A., Briggs Early, Kathaleen, ChallaSivaKanaka, Sathyavathi et al. · 2026 · Diabetes Care
10. Sex Differences in Cardiovascular Effectiveness of Newer Glucose‐Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus
    Raparelli, Valeria, Elharram, Malik, Moura, Cristiano S., Abrahamowicz, Michal, Bernatsky, Sasha, Behlouli, Hassan, Pilote, Louise · 2020 · Journal of the American Heart Association
11. Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease
    Dekkers, Claire C J, Wheeler, David C, Sjöström, C David, Stefansson, Bergur V, Cain, Valerie, Heerspink, Hiddo J L · 2018 · Nephrology Dialysis Transplantation
12. Sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease
    Patorno, Elisabetta, Htoo, Phyo T., Glynn, Robert J., Schneeweiss, Sebastian, Wexler, Deborah J., Pawar, Ajinkya, Bessette, Lily G., Chin, Kristyn, Everett, Brendan M., Kim, Seoyoung C. · 2021 · Annals of Internal Medicine
13. <p>Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide</p>
    Simes, Bryce C, MacGregor, Gordon G · 2019 · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
14. A safety update on sodium glucose co-transporter 2 inhibitors
    Fitchett, David · 2019 · Diabetes, Obesity and Metabolism
15. Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
    Kalyani, Rita R. · 2021 · New England Journal of Medicine
16. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure–Related Outcomes: Insights From the EXSCEL Trial
    Fudim, Marat, White, Jennifer, Pagidipati, Neha J., Lokhnygina, Yuliya, Wainstein, Julio, Murin, Jan, Iqbal, Nayyar, Öhman, Peter, Lopes, Renato D., Reicher, Barry et al. · 2019 · Circulation
17. Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk
    Seidelmann, Sara B., Feofanova, Elena, Yu, Bing, Franceschini, Nora, Claggett, Brian, Kuokkanen, Mikko, Puolijoki, Hannu, Ebeling, Tapani, Perola, Markus, Salomaa, Veikko et al. · 2018 · Journal of the American College of Cardiology
18. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease
    Zhang, Yaofu, Jiang, Li, Wang, Junheng, Wang, Tongxin, Chien, Chieh, Huang, Weijun, Fu, Xiaozhe, Xiao, Yonghua, Fu, Qiang, Wang, Shidong et al. · 2022 · Cardiovascular Diabetology
19. Trends in clinical characteristics and prescribing preferences for SGLT2 inhibitors and GLP-1 receptor agonists, 2013-2018.
    Dave, Chintan V., Schneeweiss, Sebastian, Wexler, Deborah J., Brill, Gregory, Patorno, Elisabetta · 2020 · Diabetes Care
20. Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide
    Januzzi, James L., Xu, Jialin, Li, JingWei, Shaw, Wayne, Oh, Richard, Pfeifer, Michael, Butler, Javed, Sattar, Naveed, Mahaffey, Kenneth W., Neal, Bruce et al. · 2020 · Journal of the American College of Cardiology
21. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial
    Clegg, Lindsay E., Penland, Robert C., Bachina, Srinivas, Boulton, David W., Thuresson, Marcus, Heerspink, Hiddo J. L., Gustavson, Stephanie, Sjöström, C. David, Ruggles, James A., Hernandez, Adrian F. et al. · 2019 · Cardiovascular Diabetology
22. SGLT2 Inhibitors and Mechanisms of Hypertension
    Briasoulis, Alexandros, Al Dhaybi, Omar, Bakris, George L. · 2018 · Current Cardiology Reports
23. Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: a meta-analysis of cardiovascular outcome trials
    Gilbert, Richard E., Thorpe, Kevin E. · 2019 · Diabetes, Obesity and Metabolism
24. Sodium-glucose cotransporter-2 inhibitors and risk of diabetic ketoacidosis among adults with type 2 diabetes: a systematic review and meta-analysis
    Colacci, Michael, Fralick, John, Odutayo, Ayodele, Fralick, Michael · 2022 · Canadian Journal of Diabetes
25. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
    Mahling, Moritz, Schork, Anja, Nadalin, Silvio, Fritsche, Andreas, Heyne, Nils, Guthoff, Martina · 2019 · Kidney and Blood Pressure Research
26. Multifactorial intervention has a significant effect on diabetic kidney disease in patients with type 2 diabetes
    Ueki, Kohjiro, Sasako, Takayoshi, Okazaki, Yukiko, Miyake, Kana, Nangaku, Masaomi, Ohashi, Yasuo, Noda, Mitsuhiko, Kadowaki, Takashi · 2021 · Kidney International
27. Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis
    Seminer, Allie, Mulihano, Alfredi, O’Brien, Clare, Krewer, Finn, Costello, Maria, Judge, Conor, O’Donnell, Martin, Reddin, Catriona · 2025 · JAMA Neurology
28. 13. Older Adults: Standards of Care in Diabetes—2026
    American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, Mandeep, McCoy, Rozalina G., Balapattabi, Kirthikaa, Bannuru, Raveendhara R., Bellini, Natalie J., Bennett, Allison K., Beverly, Elizabeth A., Briggs Early, Kathaleen, ChallaSivaKanaka, Sathyavathi et al. · 2026 · Diabetes Care
29. Management of Obesity in Cardiovascular Practice
    Després, Jean-Pierre, Carpentier, André C., Tchernof, André, Neeland, Ian J., Poirier, Paul · 2021 · Journal of the American College of Cardiology
30. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study
    Oellgaard, Jens, Gæde, Peter, Rossing, Peter, Rørth, Rasmus, Køber, Lars, Parving, Hans-Henrik, Pedersen, Oluf · 2018 · Diabetologia
31. First-Line Therapy for Type 2 Diabetes With Sodium–Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: A Cost-Effectiveness Study
    Choi, Jin G., Winn, Aaron N., Skandari, M. Reza, Franco, Melissa I., Staab, Erin M., Alexander, Jason, Wan, Wen, Zhu, Mengqi, Huang, Elbert S., Philipson, Louis et al. · 2022 · Annals of Internal Medicine
32. Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men
    Rådholm, Karin, Zhou, Zien, Clemens, Kristin, Neal, Bruce, Woodward, Mark · 2020 · Diabetes, Obesity and Metabolism
33. Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Patients With Type 2 Diabetes and Other Risk Factors for Cardiovascular Disease: A Meta-analysis
    Bhattarai, Mukul, Salih, Mohsin, Regmi, Manjari, Al-Akchar, Mohammad, Deshpande, Radhika, Niaz, Zurain, Kulkarni, Abhishek, Siddique, Momin, Hegde, Shruti · 2022 · JAMA Network Open
34. Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials
    Dicembrini, Ilaria, Nreu, Besmir, Mannucci, Edoardo, Monami, Matteo · 2019 · Diabetes, Obesity and Metabolism
35. Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes
    Garg, Vinay, Verma, Subodh, Connelly, Kim · 2019 · Progress in Cardiovascular Diseases
36. Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta-analysis of randomized controlled trials
    Yamada, Tomohide, Shojima, Nobuhiro, Noma, Hisashi, Yamauchi, Toshimasa, Kadowaki, Takashi · 2018 · Diabetes, Obesity and Metabolism
37. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
    Gallwitz, Baptist · 2022 · Frontiers in Endocrinology
38. Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors
    Lin, Donna Shu-Han, Lee, Jen-Kuang, Chen, Wen-Jone · 2021 · Diabetologia
39. Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy
    Irace, Concetta, Casciaro, Francesco, Scavelli, Faustina Barbara, Oliverio, Rosa, Cutruzzolà, Antonio, Cortese, Claudio, Gnasso, Agostino · 2018 · Cardiovascular Diabetology
40. <scp>Sodium‐glucose co‐transporter‐2</scp> inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes
    Neuen, Brendon L., Arnott, Clare, Perkovic, Vlado, Figtree, Gemma, de Zeeuw, Dick, Fulcher, Greg, Jun, Min, Jardine, Meg J., Zoungas, Sophia, Pollock, Carol et al. · 2021 · Diabetes, Obesity and Metabolism
41. <scp>SGLT2</scp> inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the <scp>HIF</scp> ‐2α signaling pathway in arrhythmogenic cardiomyopathy
    Yang, Zhe, Li, Tengling, Xian, Jianzhong, Chen, Jia, Huang, Yin, Zhang, Qin, Lin, Xiufang, Lu, Hongyun, Lin, Yubi · 2022 · The FASEB Journal
42. Monocytes and macrophages as protagonists in vascular complications of diabetes
    Kanter, Jenny E., Hsu, Cheng-Chieh, Bornfeldt, Karin E. · 2020 · Frontiers in Cardiovascular Medicine
43. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression
    Maiorino, Maria Ida, Longo, Miriam, Scappaticcio, Lorenzo, Bellastella, Giuseppe, Chiodini, Paolo, Esposito, Katherine, Giugliano, Dario · 2021 · Cardiovascular Diabetology
44. Association between sodium–glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials
    Sfairopoulos, Dimitrios, Zhang, Nan, Wang, Yueying, Chen, Ziliang, Letsas, Konstantinos P, Tse, Gary, Li, Guangping, Lip, Gregory Y H, Liu, Tong, Korantzopoulos, Panagiotis · 2022 · EP Europace
45. Cardiovascular Disease in Type 2 Diabetes: A Review of Sex-Related Differences in Predisposition and Prevention
    Al-Salameh, Abdallah, Chanson, Philippe, Bucher, Sophie, Ringa, Virginie, Becquemont, Laurent · 2019 · Mayo Clinic Proceedings
46. Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
    Staplin, Natalie, Roddick, Alistair J., Emberson, Jonathan, Reith, Christina, Riding, Alex, Wonnacott, Alexa, Kuverji, Apexa, Bhandari, Sunil, Baigent, Colin, Haynes, Richard et al. · 2021 · eClinicalMedicine
47. Canagliflozin and Stroke in Type 2 Diabetes Mellitus: Results From the Randomized CANVAS Program Trials
    Zhou, Zien, Lindley, Richard I., Rådholm, Karin, Jenkins, Bronwyn, Watson, John, Perkovic, Vlado, Mahaffey, Kenneth W., de Zeeuw, Dick, Fulcher, Greg, Shaw, Wayne et al. · 2019 · Stroke
48. Adherence and persistence rates of major antidiabetic medications: a review
    Lee, David Seung U., Lee, Howard · 2022 · Diabetology &amp; Metabolic Syndrome
49. The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
    Piperidou, Alexia, Sarafidis, Pantelis, Boutou, Afroditi, Thomopoulos, Costas, Loutradis, Charalampos, Alexandrou, Maria Eleni, Tsapas, Apostolos, Karagiannis, Asterios · 2019 · Journal of Hypertension
50. Sex disparities in cardiovascular outcome trials of populations with diabetes: a systematic review and meta-analysis
    Clemens, Kristin K., Woodward, Mark, Neal, Bruce, Zinman, Bernard · 2020 · Diabetes Care
51. Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial
    Marx, Nikolaus, Deanfield, John E., Mann, Johannes F.E., Arechavaleta, Rosario, Bain, Stephen C., Bajaj, Harpreet S., Bayer Tanggaard, Katrine, Birkenfeld, Andreas L., Buse, John B., Davicevic-Elez, Zaklina et al. · 2025 · Circulation
52. Relative and absolute risk reductions in cardiovascular and kidney outcomes with canagliflozin across KDIGO risk categories: findings from the CANVAS program
    Neuen, Brendon L., Ohkuma, Toshiaki, Neal, Bruce, Matthews, David R., de Zeeuw, Dick, Mahaffey, Kenneth W., Fulcher, Greg, Blais, Jaime, Li, Qiang, Jardine, Meg J. et al. · 2021 · American Journal of Kidney Diseases
53. Contributors to impaired bone health in type 2 diabetes
    Sheu, Angela, Greenfield, Jerry R., White, Christopher P., Center, Jacqueline R. · 2023 · Trends in Endocrinology &amp; Metabolism
54. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data
    Hallow, K. Melissa, Greasley, Peter J., Helmlinger, Gabriel, Chu, Lulu, Heerspink, Hiddo J., Boulton, David W. · 2018 · American Journal of Physiology-Renal Physiology
55. Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a glp-1ra or to basal insulin plus an SGLT2 inhibitor: Beyond, a randomized, pragmatic trial
    Giugliano, Dario, Longo, Miriam, Caruso, Paola, Di Fraia, Rosa, Scappaticcio, Lorenzo, Gicchino, Maurizio, Petrizzo, Michela, Bellastella, Giuseppe, Maiorino, Maria Ida, Esposito, Katherine · 2021 · Diabetes Care
56. AMPK is associated with the beneficial effects of antidiabetic agents on cardiovascular diseases
    Lu, Qingguo, Li, Xuan, Liu, Jia, Sun, Xiaodong, Rousselle, Thomas, Ren, Di, Tong, Nanwei, Li, Ji · 2019 · Bioscience Reports
57. Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes
    Mulder, Skander, Heerspink, Hiddo J. L., Darshi, Manjula, Kim, Jiwan J., Laverman, Gozewijn D., Sharma, Kumar, Pena, Michelle J. · 2019 · Diabetes, Obesity and Metabolism
58. An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
    Lin, Chen-Hsiu, Shao, Li, Zhang, Yu-Mei, Tu, Yu-Ju, Zhang, Yuzhen, Tomlinson, Brian, Chan, Paul, Liu, Zhongmin · 2020 · Expert Opinion on Pharmacotherapy
59. A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress
    Bray, Jonathan J.H., Foster-Davies, Harri, Stephens, Jeffrey W. · 2020 · Diabetes Research and Clinical Practice
60. Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
    Behnammanesh, Ghazaleh, Durante, Zane E., Peyton, Kelly J., Martinez-Lemus, Luis A., Brown, Scott M., Bender, Shawn B., Durante, William · 2019 · Frontiers in Pharmacology
61. The prevalence of cardiovascular disease and antidiabetes treatment characteristics among a large type 2 diabetes population in the United States.
    Weng, Wayne, Tian, Ye, Kong, Sheldon X., Ganguly, Rahul, Hersloev, Malene, Brett, Jason, Hobbs, Todd · 2019 · Endocrinology, Diabetes &amp; Metabolism
62. Therapy of Type 2 Diabetes
    Landgraf, Rüdiger, Aberle, Jens, Birkenfeld, Andreas L., Gallwitz, Baptist, Kellerer, Monika, Klein, Harald, Müller-Wieland, Dirk, Nauck, Michael A., Reuter, Hans-Martin, Siegel, Erhard · 2019 · Experimental and Clinical Endocrinology &amp; Diabetes
63. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases
    Handelsman, Yehuda, Anderson, John E., Bakris, George L., Ballantyne, Christie M., Beckman, Joshua A., Bhatt, Deepak L., Bloomgarden, Zachary T., Bozkurt, Biykem, Budoff, Matthew J., Butler, Javed et al. · 2022 · Journal of Diabetes and its Complications
64. Cardiovascular protective properties of GLP-1 receptor agonists: more than just diabetic and weight loss drugs
    Le, Richard, Nguyen, Mau T., Allahwala, Momina A., Psaltis, James P., Marathe, Chinmay S., Marathe, Jessica A., Psaltis, Peter J. · 2024 · Journal of Clinical Medicine
65. Associations of Fenofibrate Therapy With Incidence and Progression of CKD in Patients With Type 2 Diabetes
    Frazier, Rebecca, Mehta, Rupal, Cai, Xuan, Lee, Jungwha, Napoli, Sara, Craven, Timothy, Tuazon, Jennifer, Safdi, Adam, Scialla, Julia, Susztak, Katalin et al. · 2019 · Kidney International Reports
66. Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases
    Attallah, Nizar, Yassine, Lina · 2019 · Transplantation Proceedings
67. Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease
    Verma, Subodh, Al‐Omran, Mohammed, Leiter, Lawrence A., Mazer, C. David, Rasmussen, Søren, Saevereid, Hans A., Sejersten Ripa, Maria, Bonaca, Marc P. · 2022 · Diabetes, Obesity and Metabolism
68. Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profile testing: a 2019 Expert Panel Statement, Main Text
    Kolovou, Genovefa D., Watts, Gerald F., Mikhailidis, Dimitri P., Pérez-Martínez, Pablo, Mora, Samia, Bilianou, Helen, Panotopoulos, George, Katsiki, Niki, Ooi, Teik C., Lopez-Miranda, José et al. · 2019 · Current Vascular Pharmacology
69. Sodium-glucose co-transporter-2 inhibitors in non-diabetic adults with overweight or obesity: a systematic review and meta-analysis
    Zheng, Hanrui, Liu, Min, Li, Sheyu, Shi, Qingyang, Zhang, Shengzhao, Zhou, Yiling, Su, Na · 2021 · Frontiers in Endocrinology
70. Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence
    McEwan, Phil, Bennett, Hayley, Khunti, Kamlesh, Wilding, John, Edmonds, Christopher, Thuresson, Marcus, Wittbrodt, Eric, Fenici, Peter, Kosiborod, Mikhail · 2020 · Diabetes, Obesity and Metabolism
71. Antihyperglycemic therapies with expansions of US Food and Drug Administration indications to reduce cardiovascular events: prescribing patterns within an academic medical center
    Hamid, Arsalan, Vaduganathan, Muthiah, Oshunbade, Adebamike A., Ayyalasomayajula, Krishna K., Kalogeropoulos, Andreas P., Lien, Lillian F., Shafi, Tariq, Hall, Michael E., Butler, Javed · 2020 · Journal of Cardiovascular Pharmacology
72. Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial
    Heerspink, Hiddo J.L., Oshima, Megumi, Zhang, Hong, Li, Jingwei, Agarwal, Rajiv, Capuano, George, Charytan, David M., Craig, Jagriti, de Zeeuw, Dick, Di Tanna, Gian Luca et al. · 2022 · American Journal of Kidney Diseases
73. Prevalent and incident heart failure in cardiovascular outcome trials of patients with type 2 diabetes.
    Greene, Stephen J., Vaduganathan, Muthiah, Khan, Muhammad Shahzeb, Bakris, George L., Weir, Matthew R., Seltzer, Jonathan H., Sattar, Naveed, McGuire, Darren K., Januzzi, James L., Stockbridge, Norman et al. · 2018 · Journal of the American College of Cardiology
74. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome
    Ndumele, Chiadi E., Rodriguez, Fatima, Dixon, Dave L., Khan, Sadiya S., Mukherjee, Debabrata, Bajaj, Mandeep, Bangalore, Sripal, Bozkurt, Biykem, Breathett, Khadijah, Clarke, Shoa L. et al. · 2026 · JACC
75. A1C targets should be personalized to maximize benefits while limiting risks
    Riddle, Matthew C., Gerstein, Hertzel C., Holman, Rury R., Inzucchi, Silvio E., Zinman, Bernard, Zoungas, Sophia, Cefalu, William T. · 2018 · Diabetes Care
76. Type 2 diabetes and heart failure: characteristics and prognosis in preserved, mid-range and reduced ventricular function
    Johansson, Isabelle, Dahlström, Ulf, Edner, Magnus, Näsman, Per, Rydén, Lars, Norhammar, Anna · 2018 · Diabetes and Vascular Disease Research
77. Diabetes and Progression of Heart Failure
    Echouffo-Tcheugui, Justin B., Ndumele, Chiadi E., Zhang, Sui, Florido, Roberta, Matsushita, Kunihiro, Coresh, Josef, Skali, Hicham, Shah, Amil M., Selvin, Elizabeth · 2022 · Journal of the American College of Cardiology
78. Initiating therapy in patients newly diagnosed with type 2 diabetes: combination therapy vs a stepwise approach
    Cersosimo, Eugenio, Johnson, Eric L., Chovanes, Christina, Skolnik, Neil · 2018 · Diabetes, Obesity and Metabolism
79. Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus: A Need to Rethink
    Sattar, Naveed, McGuire, Darren K. · 2018 · Circulation
80. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial
    Zelniker, Thomas A., Raz, Itamar, Mosenzon, Ofri, Dwyer, Jamie P., Heerspink, Hiddo H. J. L., Cahn, Avivit, Goodrich, Erica L., Im, Kyungah, Bhatt, Deepak L., Leiter, Lawrence A. et al. · 2021 · JAMA Cardiology
81. Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: lIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial
    Blonde, Lawrence, Belousova, Lidia, Fainberg, Udi, Garcia‐Hernandez, Pedro A., Jain, Sunil M., Kaltoft, Margit S., Mosenzon, Ofri, Nafach, Jalal, Palle, Mads Sundby, Rea, Rosangela · 2020 · Diabetes, Obesity and Metabolism
82. Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: A meta-analysis update
    Salah, Husam M., Al'Aref, Subhi J., Khan, Muhammad Shahzeb, Al-Hawwas, Malek, Vallurupalli, Srikanth, Mehta, Jawahar L., Mounsey, J Paul, Greene, Stephen J., McGuire, Darren K., Lopes, Renato D. et al. · 2021 · American Heart Journal
83. Lower extremity artery disease in patients with type 2 diabetes
    Buso, Giacomo, Aboyans, Victor, Mazzolai, Lucia · 2019 · European Journal of Preventive Cardiology
84. Efficacy and safety profile of SGLT2 inhibitors in the elderly: how is the benefit/risk balance?
    Scheen, André J., Bonnet, Fabrice · 2023 · Diabetes &amp; Metabolism
85. Safety of liraglutide in type 2 diabetes and chronic kidney disease
    Mann, Johannes F.E., Fonseca, Vivian A., Poulter, Neil R., Raz, Itamar, Idorn, Thomas, Rasmussen, Søren, von Scholten, Bernt Johan, Mosenzon, Ofri, on behalf of the LEADER Trial Investigators · 2020 · Clinical Journal of the American Society of Nephrology
86. Cost-effectiveness of empagliflozin in patients with diabetic kidney disease in the United States: findings based on the EMPA-REG OUTCOME trial
    Reifsnider, Odette S., Kansal, Anuraag R., Wanner, Christoph, Pfarr, Egon, Koitka-Weber, Audrey, Brand, Sarah B., Stargardter, Matthew, Wang, Cheng, Kuti, Effie, Ustyugova, Anastasia · 2022 · American Journal of Kidney Diseases
87. GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection
    Bertoccini, Laura, Baroni, Marco Giorgio · 2020 · Advances in Experimental Medicine and Biology
88. Why the endothelium? The endothelium as a target to reduce diabetes-associated vascular disease
    Triggle, Chris R., Ding, Hong, Marei, Isra, Anderson, Todd J., Hollenberg, Morley D. · 2020 · Canadian Journal of Physiology and Pharmacology
89. Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
    Giugliano, Dario, Longo, Miriam, Scappaticcio, Lorenzo, Caruso, Paola, Esposito, Katherine · 2021 · Cardiovascular Diabetology
90. SGLT2 inhibitor treatment outcome in nonalcoholic fatty liver disease complicated with diabetes mellitus: the long-term effects on clinical features and liver histopathology
    Akuta, Norio, Kawamura, Yusuke, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Fumitaka, Suzuki, Yoshiyuki et al. · 2020 · Internal Medicine
91. SGLT2 Inhibitors in Liver Patients
    Hsiang, John Chen, Wong, Vincent Wai-Sun · 2020 · Clinical Gastroenterology and Hepatology
92. Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014–2022)
    Lin, Jialing, Pearson, Sallie-Anne, Greenfield, Jerry R., Park, Kyeong Hye, Havard, Alys, Brieger, David, Day, Richard O., Falster, Michael O., de Oliveira Costa, Juliana · 2023 · European Journal of Clinical Pharmacology
93. Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function
    van Bommel, Erik J.M., Lytvyn, Yuliya, Perkins, Bruce A., Soleymanlou, Nima, Fagan, Nora M., Koitka-Weber, Audrey, Joles, Jaap A., Cherney, David Z.I., van Raalte, Daniël H. · 2020 · Kidney International
94. Preoperative SGLT2 inhibitor use and postoperative diabetic ketoacidosis
    Dixit, Anjali A., Bateman, Brian T., Hawn, Mary T., Odden, Michelle C., Sun, Eric C. · 2025 · JAMA Surgery
95. Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors)
    Liakos, Charalampos I., Papadopoulos, Dimitrios P., Sanidas, Elias A., Markou, Maria I., Hatziagelaki, Erifili E., Grassos, Charalampos A., Velliou, Maria L., Barbetseas, John D. · 2021 · American Journal of Cardiovascular Drugs
96. Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor
    So, Anna, Sakaguchi, Kazuhiko, Okada, Yuko, Morita, Yasuko, Yamada, Tomoko, Miura, Hiroshi, Otowa-Suematsu, Natsu, Nakamura, Tomoaki, Komada, Hisako, Hirota, Yushi et al. · 2020 · Endocrine Journal
97. Poor adherence and persistence to sodium glucose co‐transporter 2 inhibitors in real‐world settings: Evidence from a systematic review and meta‐analysis
    Ofori‐Asenso, Richard, Sahle, Berhe W., Chin, Ken Lee, Mazidi, Mohsen, Ademi, Zanfina, De Bruin, Marie Louise, Liew, Danny · 2021 · Diabetes/Metabolism Research and Reviews
98. European Heart Rhythm Association (EHRA) position paper on arrhythmia management and device therapies in endocrine disorders, endorsed by Asia Pacific Heart Rhythm Society (APHRS) and Latin American Heart Rhythm Society (LAHRS)
    Gorenek, Bulent, Boriani, Giuseppe, Dan, Gheorge-Andrei, Fauchier, Laurent, Fenelon, Guilherme, Huang, He, Kudaiberdieva, Gulmira, Lip, Gregory Y H, Mahajan, Rajiv, Potpara, Tatjana et al. · 2018 · EP Europace
99. Sodium glucose co-transporter 2 inhibitors and heart failure.
    Ghosh, Raktim K., Ghosh, Gopal Chandra, Gupta, Manasvi, Bandyopadhyay, Dhrubajyoti, Akhtar, Tauseef, Deedwania, Prakash, Lavie, Carl J., Fonarow, Gregg C., Aneja, Ashish · 2019 · The American Journal of Cardiology
100. Treatment of dyslipidemia in diabetes: recent advances and remaining questions
     Chait, Alan, Goldberg, Ira · 2017 · Current Diabetes Reports